vertex pharmaceuticals incorporated notes to consolidated financial statements ( continued ) i . altus investment ( continued ) of the offering , held 450000 shares of redeemable preferred stock , which are not convertible into common stock and which are redeemable for $ 10.00 per share plus annual dividends of $ 0.50 per share , which have been accruing since the redeemable preferred stock was issued in 1999 , at vertex 2019s option on or after december 31 , 2010 , or by altus at any time . the company was restricted from trading altus securities for a period of six months following the initial public offering . when the altus securities trading restrictions expired , the company sold the 817749 shares of altus common stock for approximately $ 11.7 million , resulting in a realized gain of approximately $ 7.7 million in august 2006 . additionally when the restrictions expired , the company began accounting for the altus warrants as derivative instruments under the financial accounting standards board statement no . fas 133 , 201caccounting for derivative instruments and hedging activities 201d ( 201cfas 133 201d ) . in accordance with fas 133 , in the third quarter of 2006 , the company recorded the altus warrants on its consolidated balance sheet at a fair market value of $ 19.1 million and recorded an unrealized gain on the fair market value of the altus warrants of $ 4.3 million . in the fourth quarter of 2006 the company sold the altus warrants for approximately $ 18.3 million , resulting in a realized loss of $ 0.7 million . as a result of the company 2019s sales of altus common stock and altus warrrants in 2006 , the company recorded a realized gain on a sale of investment of $ 11.2 million . in accordance with the company 2019s policy , as outlined in note b , 201caccounting policies , 201d the company assessed its investment in altus , which it accounts for using the cost method , and determined that there had not been any adjustments to the fair values of that investment that would require the company to write down the investment basis of the asset , in 2005 and 2006 . the company 2019s cost basis carrying value in its outstanding equity and warrants of altus was $ 18.9 million at december 31 , 2005 . j . accrued expenses and other current liabilities accrued expenses and other current liabilities consist of the following at december 31 ( in thousands ) : k . commitments the company leases its facilities and certain equipment under non-cancelable operating leases . the company 2019s leases have terms through april 2018 . the term of the kendall square lease began january 1 , 2003 and lease payments commenced in may 2003 . the company had an obligation under the kendall square lease , staged through 2006 , to build-out the space into finished laboratory and office space . this lease will expire in 2018 , and the company has the option to extend the term for two consecutive terms of ten years each , ultimately expiring in 2038 . the company occupies and uses for its operations approximately 120000 square feet of the kendall square facility . the company has sublease arrangements in place for the remaining rentable square footage of the kendall square facility , with initial terms that expires in april 2011 and august 2012 . see note e , 201crestructuring 201d for further information. .

Table:
 | 2006 | 2005
research and development contract costs | $ 57761 | $ 20098
payroll and benefits | 25115 | 15832
professional fees | 3848 | 4816
other | 4635 | 1315
total | $ 91359 | $ 42061
research and development contract costs $ 57761 $ 20098 payroll and benefits 25115 15832 professional fees 3848 4816 4635 1315 $ 91359 $ 42061 .

Question: as part of the restructuring additional information what was the percent of the 2 research and development contract costs to the total cost in 2006
Answer: 63.2%
Calculation: divide(57761, 91359)